Feasibility and Efficacy of Low-profile Visual Intraluminal Support Device: A Single Center Five-year Experience.


Journal

Current neurovascular research
ISSN: 1875-5739
Titre abrégé: Curr Neurovasc Res
Pays: United Arab Emirates
ID NLM: 101208439

Informations de publication

Date de publication:
2021
Historique:
received: 29 04 2021
revised: 14 05 2021
accepted: 21 05 2021
pubmed: 14 9 2021
medline: 5 4 2022
entrez: 13 9 2021
Statut: ppublish

Résumé

The Low-Profile Visualized Intraluminal Support (LVIS) devices are a new generation of self-expandable, high-porosity stents approved for the treatment of large to giant wide-necked intracranial aneurysms via stent-assisted coiling. Here we report the radiographic and clinical outcomes seen with LVIS, LVIS Jr. and LVIS Blue from a single institution over a fiveyear period. Patients with intracranial aneurysms treated by LVIS, LVIS Jr. and LVIS Blue technology over a five-year period (2012 - 2017) at our institution were retrospectively reviewed. Seventy-four patients (55 females and 19 males; average age = 59.2) with 74 aneurysms underwent embolization of intracranial aneurysms using LVIS (N = 10), LVIS Jr. (N = 47) or LVIS Blue (N = 12) devices at our institution over the study period. The most common location of treated aneurysms was the anterior communicating artery (31%), followed by the basilar artery (19%), and the middle cerebral artery (13%). The mean neck and dome sizes were 3.9±1.5mm and 6.6±3.2mm, respectively. The median follow-up time was 6 months. At the last radiographic follow- up, 93.1% of patients had complete occlusion (RR-I or OKM-D). In 5 cases (7%), the LVIS stent failed to open, requiring balloon angioplasty (N = 3) or stent recapture and use of a non-LVIS branded device (N = 2). Five patients had post-embolization infarcts, and 1 patient had an intra-operative dome rupture. LVIS brand of stents is a safe, effective, and technically feasible treatment strategy for wide-neck intracranial aneurysms, with high deployment success and aneurysm obliteration rates.

Identifiants

pubmed: 34515001
pii: CNR-EPUB-117859
doi: 10.2174/1567202618666210910123134
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

279-286

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Vitaliy Davidov (V)

Texas A&M College of Medicine, 8447 Bryan Rd, Bryan, TX 77807, USA | Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Saeed Sadrameli (S)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Virendra Desai (V)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Jonathan Lee (J)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Ryan Austerman (R)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Amanda Jenson (A)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Zain Boghani (Z)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Gavin Britz (G)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Orlando Diaz (O)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Richard P Klucznik (RP)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Yi Jonathan Zhang (YJ)

Department of Neurosurgery, Houston Methodist Cerebrovascular Center, 6565 Fannin St, Houston, TX 77030, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH